financial guidance
Quanterix Q1 Revenues Fall 5 Percent
The company lowered its full-year 2025 revenue guidance, citing the impact of tariffs, cuts to academic funding, and lower biopharma spending.
The firm booked $154.9 million in Q1 revenues, including $16.8 million in license and royalty revenues from the patent litigation settlement with Vizgen.
Natera Ramping up R&D, Commercial Spending as Q1 Product Revenues Rise 37 Percent, Beat Estimates
Premium
The firm trimmed its Q1 net loss and has begun investing heavily in R&D and commercial operations to drive future growth.
The firm expects 2025 revenues to shrink versus the prior year and business in China to dry up over the course of the year.
OraSure's Q1 Core Revenues Down 2 Percent
The firm brought in revenues of $29.9 million in Q1, down 45 percent from $54.1 million in Q1 2024 but narrowly beating the consensus Wall Street estimate of $29.6 million.